LatestMalaria vaccine add-ons activate three antibody targets, study finds
Cannabis

VA Launches Phase 3 Psilocybin Trial for Veterans with Treatment-Resistant Depression

Raúl del Pino
DepressionPTSDMajor Depressive Disorder
Summary

The U.S. Department of Veterans Affairs has activated a groundbreaking Phase 3 clinical trial investigating psilocybin as a treatment for treatment-resistant depression and concurrent PTSD in veterans. This represents a significant shift in how the VA explores novel psychedelic-assisted therapies for service members who have not responded to conventional antidepressant medications. The trial builds on promising Phase 2 data showing psilocybin's potential to rapidly reduce depressive symptoms when combined with professional psychological support. This initiative offers hope to thousands of veterans struggling with depression that hasn't improved with standard treatments, potentially expanding therapeutic options within the military healthcare system.

Originally published on

Cannabis Magazine

By Raúl del Pino

Read full article(opens in new tab)

Fetched: August 8, 2026 at 10:04 AM

Related News

More news you might be interested in

View all
Cannabis
Parkinson's Disease

Phase 2 Trial Shows Cannabis Oil Does Not Improve Parkinson's Symptoms

A Phase 2 clinical trial published in Movement Disorders on August 7 found that cannabis oil did not provide meaningful improvements for pain and non-motor symptoms in Parkinson's disease patients. The study tempers growing expectations about cannabis as a therapeutic option for this neurodegenerative condition. While some patients report subjective benefits, this rigorous clinical evidence suggests cannabis oil may not be an effective treatment for Parkinson's-related pain and non-motor complications. The findings highlight the importance of evidence-based research in evaluating cannabis therapeutics before widespread medical use.

8 hours ago
Cannabis Magazine
MJBizDaily
Cannabis

Massachusetts Town Ordered to Pay Cannabis Industry $2 Million in Misused Funds

A Massachusetts court ruled that a city must repay three cannabis retailers over $2 million for funds the municipality improperly spent on road improvements and other expenses unrelated to cannabis regulation. The judgment highlights ongoing tensions between municipalities and regulated cannabis businesses over licensing fees and fund allocation. This case underscores the importance of transparent financial practices in cannabis licensing and demonstrates that courts are holding local governments accountable for misappropriating cannabis-related revenues. The ruling sets a precedent for other jurisdictions managing cannabis business taxes and fees to ensure proper fiscal responsibility.

16 hours ago
MJBizDaily
High Times 50th Anniversary: Seven Artists Reimagine the Cannabis Plant Through Art
Cannabis

High Times 50th Anniversary: Seven Artists Reimagine the Cannabis Plant Through Art

High Times celebrated its 50th anniversary with a special printed edition featuring seven artists who each created unique artistic interpretations of the cannabis plant. The project began with a detailed family portrait drawing that took 144 hours to complete. Artists were given creative freedom to explore their own visual perspectives on cannabis culture and botany. This artistic collaboration showcases how cannabis has become a legitimate subject for serious artistic expression across multiple mediums and styles. The anniversary edition highlights the cultural significance of cannabis in contemporary art and media.

17 hours ago
El Planteo
MJBizDaily
Cannabis

New York Legalizes Cannabis Sales at Farmers' Markets and Pop-Up Events

New York has expanded cannabis access by allowing licensed cannabis microbusinesses to sell their products at pop-up venues, including farmers' markets and community events. This regulatory development increases availability and convenience for patients seeking cannabis-based therapeutic options. The policy supports small-scale cannabis entrepreneurs while creating more accessible distribution channels for medical cannabis consumers. For patients managing chronic conditions, this expansion may facilitate easier access to licensed, regulated products with verified potency and safety standards. The move reflects evolving state policies recognizing the role of cannabis in therapeutic applications.

17 hours ago
MJBizDaily